Association for Research in Vision and Ophthalmology (ARVO)--2010 Annual Meeting. For Sight: The Future of Eye and Vision Research--part 1.

Abstract

The 2010 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO), held in Fort Lauderdale, FL, USA, included topics covering new therapeutic developments in the field of eye and vision research. This conference report highlights selected presentations on the development of FOV-2304 (Fovea Pharmaceuticals SA) for the potential treatment of diabetic macular edema; PHA-666859 (Pfizer Inc) for diabetic retinopathy; GTx-878 (GTx Inc) and FCFD-4514S (Genentech Inc) for age-related macular degeneration; SYL-040012 (Sylentis Sau) for ocular hypertension associated with open-angle glaucoma; PEG-PLA-TNP-470 (Harvard Medical School) for ocular neovascularization; recombinant galectin-3 (Senju Pharmaceutical Co Ltd) for corneal injury; and CellBead Neuro (CellMed Inc) for neurological trauma and neurodegeneration.

• Authors: Livia Hookes
• Journal: IDrugs : the investigational drugs journal (IDrugs) Vol. 13 Issue 7 Pg. 427-9 (Jul 2010) ISSN: 2040-3410 [Electronic] England
• PMID: 20582862 (Publication Type: Congress)

Chemical References

• Drugs, Investigational

Topics

• Animals
• Brain Injuries (complications, therapy)
• Drug Evaluation, Preclinical
• Drugs, Investigational (pharmacology)
• Eye Diseases (complications, drug therapy, immunology)
• Humans
• Nerve Degeneration (complications, therapy)
• Stem Cell Transplantation (methods)
• Vision Disorders (complications, drug therapy, immunology)